Alpha Cognition, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).

ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration.

ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
Ticker:
ACOG
Exchange:
TSX-V
Company Type:
Publicly Traded Company
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Alpha-1062
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Alpha Cognition, Inc